Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update

Rhea-AI Summary

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced a conference call on February 11, 2021, at 5 pm ET, to discuss its fourth-quarter and full-year financial results for 2020. The call will provide a corporate update and insights into the company’s progress in developing novel treatments for serious rare and ultra-rare genetic diseases. The information will be accessible through their website, with a dedicated phone line for participants.

Positive

• Established a call for discussing Q4 and annual financial results, indicating transparency and responsiveness to investors.
• Focus on developing therapies for rare diseases addresses high unmet medical needs.

Negative

• None.

NOVATO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, February 11, 2021 at 5pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2020.

The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call by phone, dial (855) 797-6910 (USA) or (262) 912-6260 (International) and enter the passcode 6391931. The replay of the call will be available for one year.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com

Contact:
Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-475-6370

FAQ

When is Ultragenyx Pharmaceutical's conference call to discuss financial results for Q4 2020?

The conference call is scheduled for February 11, 2021, at 5 pm ET.

How can I participate in Ultragenyx Pharmaceutical's conference call?

You can join the call by phone at (855) 797-6910 for the USA or (262) 912-6260 for international participants.

What is the purpose of the February 11, 2021, conference call for Ultragenyx Pharmaceutical?

The call will discuss the financial results and corporate update for the fourth quarter and year ending December 31, 2020.

Where can I access the recording of Ultragenyx Pharmaceutical's conference call?

The replay will be available through the company's website for one year after the call.